IceCure Medical Ltd. (NASDAQ:ICCM – Free Report) – Equities researchers at Brookline Capital Markets decreased their FY2030 earnings per share (EPS) estimates for IceCure Medical in a note issued to investors on Wednesday, August 12th. Brookline Capital Markets analyst K. Dolliver now forecasts that the company will earn $2.98 per share for the year, down from their prior estimate of $3.21. The consensus estimate for IceCure Medical’s current full-year earnings is ($3.51) per share.
A number of other research firms have also recently weighed in on ICCM. Alliance Global Partners started coverage on shares of IceCure Medical in a research report on Monday, May 4th. They set a “buy” rating for the company. Weiss Ratings restated a “sell (e+)” rating on shares of IceCure Medical in a research report on Friday, July 17th. Maxim Group dropped their price objective on IceCure Medical from $90.00 to $30.00 and set a “buy” rating for the company in a research note on Thursday, May 14th. Finally, Wall Street Zen upgraded IceCure Medical to a “sell” rating in a report on Sunday, July 12th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $52.50.
IceCure Medical Stock Performance
IceCure Medical stock opened at $3.00 on Friday. The company’s 50 day simple moving average is $3.95 and its 200-day simple moving average is $9.83. The company has a market capitalization of $10.29 million, a price-to-earnings ratio of -0.35 and a beta of 0.47. IceCure Medical has a 1 year low of $2.12 and a 1 year high of $42.00.
IceCure Medical (NASDAQ:ICCM – Get Free Report) last posted its earnings results on Tuesday, June 30th. The company reported ($1.64) EPS for the quarter. IceCure Medical had a negative net margin of 427.67% and a negative return on equity of 188.60%. The business had revenue of $0.91 million during the quarter.
Hedge Funds Weigh In On IceCure Medical
Several hedge funds and other institutional investors have recently made changes to their positions in ICCM. Jane Street Group LLC purchased a new stake in shares of IceCure Medical during the fourth quarter worth approximately $67,000. Concurrent Investment Advisors LLC purchased a new stake in shares of IceCure Medical in the 4th quarter valued at approximately $48,000. Finally, Virtu Financial LLC acquired a new stake in shares of IceCure Medical in the 4th quarter valued at $39,000. Hedge funds and other institutional investors own 0.62% of the company’s stock.
About IceCure Medical
IceCure Medical Ltd. (NASDAQ: ICCM) is a clinical-stage medical device company specializing in the development and commercialization of proprietary cryoablation systems for the treatment of tumors and other pathological tissues. The company’s core technology employs a unique liquid-nitrogen-based platform to deliver rapid cooling through fine-gauge cryoprobes, enabling precise and minimally invasive tissue ablation under imaging guidance. IceCure’s lead product, ProSense, is designed to offer a single-probe approach that can be deployed in an outpatient setting, reducing procedure time and patient recovery periods.
Originally founded in Israel, IceCure Medical obtained its first CE mark for the treatment of benign breast tumors and fibroadenomas in 2017.
Featured Stories
- Five stocks we like better than IceCure Medical
- Is Lockheed Martin Gearing Up to Lead Defense Stocks?
- Inside Teledyne’s Bold Bet on the Future of Medical Imaging
- Why Are Analysts Freaking Out About Apple’s All-Glass iPhone?
- Asian Market Circuit Breakers Hit Stocks, Not AI Demand
Receive News & Ratings for IceCure Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IceCure Medical and related companies with MarketBeat.com's FREE daily email newsletter.
